Skip to main content
Top
Published in: Experimental Hematology & Oncology 1/2012

Open Access 01-12-2012 | Editorial

Publish, not perish: Introducing Experimental Hematology & Oncology

Authors: Zihai Li, Chung-Tsen Hsueh, Delong Liu

Published in: Experimental Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

As a scientific discipline, medicine can only be advanced by experimentation. Experimentation could either validate or refute a hypothesis. Unfortunately, today's publication climate strongly favors publication of positive research findings, especially with clinical trials. Experimental Hematology & Oncology (e HO) is a new open access online journal that emphasizes preclinical, patient-oriented and translational aspects of research. The journal differentiates from others in the field by making a deliberate effort in publishing clinical trials with "negative" results and basic science studies with provocative findings. The focus of the peer-review mechanism for e HO will be on the technical merit of the study and not on demanding a long list of additional experiments that hinders rapid information dissemination.
Metadata
Title
Publish, not perish: Introducing Experimental Hematology & Oncology
Authors
Zihai Li
Chung-Tsen Hsueh
Delong Liu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Experimental Hematology & Oncology / Issue 1/2012
Electronic ISSN: 2162-3619
DOI
https://doi.org/10.1186/2162-3619-1-1

Other articles of this Issue 1/2012

Experimental Hematology & Oncology 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine